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TrkB-enhancer facilitates functional 
recovery after traumatic brain 
injury
John Marshall1, Joanna Szmydynger-Chodobska2, Mengia S. Rioult-Pedotti1, Kara Lau1, 
Andrea T. Chin2, Siva K. Reddy Kotla3, Rakesh Kumar Tiwari3, Keykavous Parang3, 
 Steven W. Threlkeld4 & Adam Chodobski2
Brain-derived neurotrophic factor (BDNF), a key player in regulating synaptic strength and learning, 
is dysregulated following traumatic brain injury (TBI), suggesting that stimulation of BDNF 
signaling pathways may facilitate functional recovery. This study investigates whether CN2097, a 
peptidomimetic ligand which targets the synaptic scaffold protein, postsynaptic density protein 95, 
to enhance downstream signaling of tropomyosin-related kinase B, a receptor for BDNF, can improve 
neurological function after TBI. Moderate to severe TBI elicits neuroinflammation and c-Jun-N-terminal 
kinase (JNK) activation, which is associated with memory deficits. Here we demonstrate that CN2097 
significantly reduces the post-traumatic synthesis of proinflammatory mediators and inhibits the post-
traumatic activation of JNK in a rodent model of TBI. The recordings of field excitatory post-synaptic 
potentials in the hippocampal CA1 subfield demonstrate that TBI inhibits the expression of long-term 
potentiation (LTP) evoked by high-frequency stimulation of Schaffer collaterals, and that CN2097 
attenuates this LTP impairment. Lastly, we demonstrate that CN2097 significantly improves the 
complex auditory processing deficits, which are impaired after injury. The multifunctionality of CN2097 
strongly suggests that CN2097 could be highly efficacious in targeting complex secondary injury 
processes resulting from neurotrauma.
Traumatic brain injury (TBI), which encompasses a wide spectrum of injuries from mild to severe, has been 
regarded as a “silent epidemic of modern society”1. For patients who survive the initial trauma, morbidity and 
mortality are largely determined by the severity of secondary injury resulting from pathophysiological processes 
that lead to neuronal death2. The initial injury in TBI triggers glutamate release leading to hyperactivation of 
N-methyl-D-aspartate (NMDA)-type receptors (NMDARs), calcium (Ca2+) overload, and secondary neuronal 
death due to excitotoxicity3. However, anti-excitotoxic treatment with NMDAR antagonists has not yielded ben-
eficial clinical effects3. NMDARs, which are down-regulated shortly after injury4, also mediate pro-survival sig-
naling3, suggesting that interventions that promote NMDAR activity may be beneficial5. Furthermore, NMDAR 
activity plays a key role in cognition, being important for long-term potentiation (LTP), an activity-dependent 
strengthening of glutamatergic synapses6. Recent strategies for attenuating excitotoxic signaling have used pep-
tidic compounds to disrupt the interaction of ionotropic glutamate receptors with the PDZ (PSD-95/Discs-large/
ZO-1 homology) domains of the postsynaptic density protein (PSD)-95, an intracellular scaffold protein that 
couples ionotropic glutamate receptors to neuronal death pathways7. NMDAR-dependent cortical neuronal death 
is disrupted by a peptide mimicking the NR2B PDZ ligand (TAT-NR2B9c)8. PSD-95 also links the kainate recep-
tor (GRIK2) with c-Jun-N-terminal kinase (JNK) activation9, and a peptide designed against the C-terminus 
of GRIK2, Tat-GluR6-9c, showed a protective effect against neuronal death induced by cerebral ischemia/
reperfusion10.
Brain-derived neurotrophic factor (BDNF) is a key player in long-lasting increases in synaptic strength and 
learning6, and therapeutic strategies to enhance BDNF signaling after TBI could facilitate recovery11. BDNF binds 
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to the tropomyosin-related kinase B (TrkB) receptor, which results in activation of downstream phosphatidylin-
ositol 3-kinase (PI3K)-Akt, mitogen-activated protein kinase (MAPK) ERK, and PLC-γ signaling12, that pro-
mote neuronal survival13. Increased levels of glutamate activate microglia2, to release proinflammatory cytokines, 
such as tumor necrosis factor-α (TNF-α) and interleukin-1β (IL-1β)14, 15, to suppress BDNF-dependent signa-
ling and LTP16. Tumor necrosis factor-α potentiates glutamate-mediated cell death by rapidly increasing sur-
face expression of Ca2+ permeable-AMPA and NMDARs17, connecting neuroinflammation and excitotoxicity. 
The NMDAR partial agonist D-cycloserine has been shown to induce expression of BDNF, restore impaired 
hippocampal LTP, and improve cognitive function in a TBI model5, and treatment with 7,8-dihydroxyflavone 
(DHF), a small molecule imitating BDNF, protected hippocampal neurons18. In a recent study, we reported a 
novel PSD-95 binding peptidomimetic ligand, CN2097, that significantly up-regulated TrkB signaling12. CN2097 
binding to PSD-95 promotes PSD-95 recruitment to TrkB to enhance BDNF-mediated PLCγ-CaMKII and 
PI3K-Akt signaling, but not ERK, to facilitate LTP in the hippocampus12. CN2097 consists of a cyclized pep-
tide, KNYKKTEV, incorporating a β-alanine lactam side-chain linker between the valine (V) and threonine (T) 
residues of the PDZ-binding moiety19, conjugated with a disulfide bond to a polyarginine (R7) active-transport 
moiety (R7-CC-YK[KTE(β-Ala)]V)19, 20. In contrast to previously reported PSD-95 PDZ-binding peptides that 
disrupt the function of PSD-9521, CN2097 facilitates LTP12 and pro-survival signaling13.
Here we demonstrate that CN2097 has the ability to mitigate secondary injury by decreasing the production 
of proinflammatory mediators as well as the influx of leukocytes to the injured brain. As acute inflammation 
reduces LTP22, we evaluated the effect of CN2097 on LTP using an in vitro brain slice preparation, finding that 
CN2097 prevents deficits of LTP resulting from TBI. Auditory sensory assessment, employed to gauge the mag-
nitude of neurological dysfunction and functional outcome after TBI, demonstrates CN2097’s ability to improve 
complex auditory tone-order discrimination that has been linked to language deficits in patients sustaining TBI23. 
Although the single dose of CN2097 tested in this study did not improve all therapeutic endpoints routinely eval-
uated in experimental TBI, taken together, our results strongly suggest that CN2097 could be highly efficacious in 
targeting complex secondary injury processes resulting from neurotrauma.
Results
CN2097 reduces post-traumatic neuroinflammation in the injured cerebral cortex. The ability 
of TrkB signaling to be neuroprotective in neuroinflammatory settings24, 25, prompted us to test if CN2097, a pep-
tidomimetic compound enhancing downstream TrkB signaling12, can attenuate the brain inflammatory response 
to injury. Tumor necrosis factor-α and IL-1β are proinflammatory cytokines stimulating leukocyte influx, causing 
glial activation, and contributing to neuronal cell loss and blood–brain barrier (BBB) dysfunction15. In rodent 
models of TBI, brain concentrations of TNF-α and IL-1β increase rapidly after injury, but then return to basal 
levels within 24 h post-TBI26. Here we show that post-injury treatment with CN2097, injected at 1 and 2 h post-
TBI, significantly lowered the synthesis of both TNF-α and IL-1β (Fig. 1A). As decreased production of these two 
proinflammatory cytokines is anticipated to dampen the inflammatory cascade, we also evaluated the magnitude 
Figure 1. Therapeutic efficacy of CN2097 in reducing post-traumatic neuroinflammation in the injured 
cerebral cortex. Western blot analysis was performed on cortical samples following CCI. Rats were injected 
i.p. with CN2097 (10 mg/kg) or vehicle (0.9% NaCl) at 1 and 2 h post-TBI (n = 4 rats/group). Cortical samples 
were collected at 4 h (A) or 24 h (B) after TBI. (A) CN2097 significantly lowered the post-traumatic production 
of TNF-α and IL-1β at 4 h post-TBI. The fully processed, biologically active forms of these proinflammatory 
cytokines are shown. C: contralateral, uninjured cortex. (B) CN2097 inhibited the post-traumatic influx of 
monocytes to the injured cortex, as assessed by the level of expression of CD68, and reduced the synthesis of 
MMP9 (pro-MMP9 is shown) at 24 h post-TBI. The expression of CD68 and pro-MMP9 was undetectable in 
the contralateral cortex. Data represent mean ± SEM. The images shown are cropped. The full-length original 
images are shown in Fig. S1.
www.nature.com/scientificreports/
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of influx of leukocytes to the injured cortex. Focusing on monocytes, whose influx to the injured brain could 
be readily assessed by the levels of expression of CD68 at 1 d post-TBI26, we found that CN2097 reduces the 
post-traumatic influx of these inflammatory cells (Fig. 1B, upper panel). Because invading leukocytes carry and 
then release matrix metalloproteinases, we examined whether CN2097 would also have an effect on post-trau-
matic expression of matrix metalloproteinase 9 (MMP9), a metalloproteinase known to disrupt the integrity of 
the BBB15. The level of MMP9 assessed in the ipsilateral cortex at 24 h post-TBI was found to be significantly 
lower in CN2097-treated rats compared to vehicle-injected animals (Fig. 1B, lower panel). These results sug-
gest that CN2097 exhibits anti-inflammatory properties by reducing the production of upstream mediators of 
inflammation.
CN2097 attenuates TBI-induced hippocampal LTP deficits. The hippocampus is highly vulnerable to 
neurotrauma, which leads to cognitive impairment27. The long-lasting increases in synaptic strength and learning 
in the hippocampus are highly dependent on BDNF28, and proinflammatory cytokines, such as IL-1β, can disrupt 
BDNF signaling cascades and inhibit LTP16, 22. It has been shown that IL-1β activates JNK, and that the inhibitory 
effect of lL-1β on LTP could be reversed by selective inhibition of JNK catalytic activity29. Three genes, JNK1, 
JNK2, and JNK3, encode the JNK proteins, and we have previously demonstrated that TBI results in a significant 
increase in activity of JNK1 and JNK2, whereas the activity of JNK3, which is high in both the contralateral hem-
isphere and in sham-injured animals, is not affected by the impact26. In contrast to JNK3, the activity of JNK1 
and JNK2 in the contralateral hemisphere and in sham-injured rats was found to be low. When an antibody 
recognizing the phosphorylated forms of all three JNKs was used on immunoblots of protein extracts from the 
hippocampus, we found no difference in the level of JNK activation between the ipsilateral and contralateral hem-
ispheres of vehicle-treated rats (Fig. 2), which was consistent with our previous observations26. In comparison, 
there was a significant reduction in JNK activity in the ipsilateral hippocampus in CN2097- versus vehicle-treated 
rats (Fig. 2). These findings suggest that CN2097 has the ability to mitigate the post-traumatic activation of JNK.
As discussed above, an increase in JNK activity can disrupt LTP and hippocampal-dependent learning fol-
lowing TBI22. Therefore, we examined whether CN2097 could attenuate TBI-induced deficits in LTP. Long-term 
potentiation has been reported to be impaired in the CA1 area of the hippocampus at 2–3 days post-injury30–32, 
whereas others did not observe an LTP deficit27. Using the CCI model of TBI, we examined the capacity for LTP 
induction in the ipsilateral and contralateral hemispheres. Rats received intraperitoneal (i.p.) injections of vehicle 
at 1 and 2 h post-TBI. Hippocampal slices were prepared at 1 and 3 days after CCI injury for extracellular record-
ings. Extracellular field potentials (fEPSPs) evoked at hippocampal CA1 pyramidal cells by the electrical stimu-
lation of the Schaffer collateral-commissural pathway were recorded at 0.33 Hz. The stimulation intensity used 
was adjusted to the intensity generating half-maximal response amplitudes in both hemispheres. After recording 
a stable baseline for more than 20 min, LTP was induced by 2 sets of high frequency stimulation (HFS, 2 × 100 Hz 
for 1 s, 20 s apart). As shown in Fig. 3, rats receiving vehicle exhibited deficits in LTP in the ipsilateral (Ipsi-Hip) 
relative to the contralateral (Contra-Hip) hippocampal slice at 1 d (Fig. 3A1) and 3 d (Fig. 3A2) after injury. In 
the ipsilateral hippocampus, LTP was significantly impaired (104.6 ± 2.3%, n = 8) compared to the contralateral 
hippocampus (158.9 ± 5.4, n = 7, p < 0.0005; Ipsi/Contra ratio = 0.66) (Fig. 3B1) at 1 d after TBI and vehicle treat-
ment. A similar interhemisphere difference (Ipsi: 106.3 ± 3.4, n = 12, Contra: 157.0 ± 7.1, n = 11, p < 0.0005; Ipsi/
Contra ratio = 0.68) was observed 3 d after vehicle treatment (Fig. 3A2, left; 3B2, left).
Next we tested whether CN2097 could ameliorate the LTP deficits caused by neurotrauma. Rats were injected 
i.p. with CN2097 at 1 and 2 h post-TBI. At 1 d after TBI combined with CN2097 treatment, LTP was restored in 
Figure 2. CN2097 reduces JNK activity in the injured ipsilateral hippocampus. Western blots showing that 
CN2097 significantly lowered the level of phosphorylation of JNK (p-JNK) in the ipsilateral hippocampus 
24 h after TBI. The bar graph illustrates quantitative data of the optical density of p-JNK normalized to JNK 
(mean ± SEM, *p < 0.05). Animals were injected i.p. with CN2097 (10 mg/kg) or vehicle (0.9% NaCl) at 1 and 
2 h post-TBI (n = 3 rats/group), and the hippocampal samples were collected at 24 h after TBI. The images 
shown are cropped. The full-length original images are shown in Fig. S2.
www.nature.com/scientificreports/
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the ipsilateral hippocampus (142.6 ± 2.5, n = 7) to a level that was not significantly different from that observed 
in the contralateral hippocampus (141.6 ± 10.9, n = 5, p = 0.91; Ipsi/Contra ratio = 1.01) (Fig. 3A1 and B1, right). 
Similarly, at 3 d following CN2097 treatment, LTP was not significantly different in the ipsilateral (155.8 ± 6.4, n = 10) 
versus the contralateral hippocampus (160.1 ± 8.8, n = 6, p = 0.87; Ipsi/Contra ratio = 0.97) (Fig. 3A2 and B2, 
right). Interhemisphere ratios (Ipsi/Contra) of LTP for all treatment groups summarized in Fig. 3C suggest that 
CN2097 injected 1 and 2 h following TBI can restore LTP at 1 and 3 days after injury.
To explore whether presynaptic transmitter release is involved in the suppressed LTP caused by TBI, we 
stimulated hippocampal slices with two pulses separated by 50 ms. The probability of transmitter release can be 
quantified by the amplitude ratio of the second to the first pulse. As shown in Fig. 4A, we observed no difference 
in the paired pulse ratio (PPR) between ipsilateral and contralateral hemispheres at 1 d (Ipsi: BL 1.67 ± 0.02, 
LTP 1.63 ± 0.03, n = 12; Contra: BL 1.86 ± 0.22, LTP 1.71 ± 0.20, n = 8) and 3 d (Ipsi: BL 1.54 ± 0.05, LTP 
1.40 ± 0.06, n = 13; Contra: BL 1.62 ± 0.02, LTP 1.55 ± 0.03, n = 13) after TBI and vehicle injection. Similar results 
were obtained at 1 and 3 days in rats that received CN2097 injections at 1 and 2 h following TBI (1 d: Ipsi: BL 
1.80 ± 0.022, LTP 1.72 ± 0.21, n = 8; Contra: BL 1.79 ± 0.06, LTP 1.75 ± 0.08, n = 5; 3 d: Ipsi: BL 1.74 ± 0.04, LTP 
1.59 ± 0.03, n = 10; Contra: BL 1.73 ± 0.06, LTP 1.67 ± 0.09, n = 6) (Fig. 4A). Interhemisphere ratios (Ipsi/Contra) 
were not different at 1 and 3 days whether rats were treated with vehicle (0.9 and 0.95, respectively) or CN2097 
(1.01 and 1.00, respectively) at baseline (Fig. 4C, left) or after LTP (vehicle: 0.95 and 0.91, respectively; CN2097: 
0.99 and 0.95, respectively; Fig. 4C, right). These results suggest a non-presynaptic mechanism to be involved in 
TBI-induced LTP deficits and LTP restoration in the presence of CN2097.
The effect of CN2097 on neurobehavioral outcomes after TBI. We evaluated the efficacy of CN2097 
on behavioral tasks related to spatial learning and sensory processing, deficits of which have been observed in 
TBI patients33, 34. A timeline for these behavioral studies, including relative dose timing and weeks of Morris water 
maze (MWM) and auditory testing, is shown in Fig. 5. Hippocampal-dependent spatial learning is vulnerable to 
brain injury35 and can result in the inability to navigate a novel environment33. To determine if CN2097 treatment 
Figure 3. CN2097 attenuates TBI-induced hippocampal LTP deficits. Rats were injected i.p. with CN2097 
(10 mg/kg) or vehicle (0.9% NaCl) at 1 and 2 h post-TBI. Extracellular field potentials (fEPSP) to Schaffer 
Collateral stimulation were recorded in CA1 at 1 and 3 days following treatment. (A) LTP was recorded in both 
the contralateral (Contra-Hip) and ipsilateral (Ipsi-Hip) hippocampal slices at 1 d (A1) and 3 d (A2) following 
vehicle (left) and CN2097 treatment (right). Left: Following TBI, LTP (2 × 100 Hz for 1 s, 20 s apart; arrows) 
was impaired in the ipsilateral (Ipsi-Hip, red), but not the contralateral hippocampus (Contra-Hip, black). 
Right: CN2097 restored LTP to control levels. Field EPSP slopes in the CA1 region are plotted as a percentage 
of baseline. Insets: Examples of fEPSP traces representing averages of 20 responses at baseline and LTP (Contra, 
black; Ipsi, red). (B) Group data of LTP in vehicle- and CN2097-injected rats at 1 d (B1) and 3 d (B2) following 
TBI. (B1) At 1 d after TBI and vehicle treatment, LTP was significantly impaired in the ipsilateral compared to 
contralateral hippocampus. After CN2097 treatment, LTP was restored in the ipsilateral hippocampus to a level 
that was not significantly different from that observed in the contralateral hippocampus. (B2) At 3 d following 
TBI, synaptic plasticity was similarly restored. In CN2097-treated rats, LTP in the ipsilateral hippocampus 
was not different from that observed in the contralateral hippocampus, while vehicle treatment resulted in 
a significant interhemisphere difference (C). Interhemisphere ratio (Ipsi/Contra) of LTP indicates highly 
impaired LTP in the ipsilateral hemisphere of vehicle-treated rats (yellow) when compared to CN2097-treated 
rats (blue) at 1 d as well as at 3 d post-TBI. Data represent mean ± SEM.
www.nature.com/scientificreports/
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after TBI impacts spatial learning and memory, rats underwent the MWM testing for 5 d, followed by a single 
probe trial. Results from 2 treatments (TBI-vehicle, n = 6, and TBI-CN2097, n = 8) by 5 d repeated measures 
ANOVA showed that both groups performed similarly across all days of testing with all rats significantly improv-
ing from day one to day five (F(4,48) = 25.2, p < 0.001) (Fig. 6A). Similarly, results from the probe trial (Fig. 6B), 
a final swim in which the platform was removed, indicated that both treatment groups spent more time in the 
former platform zone, when compared to the non-platform zones, indicating intact memory for the former plat-
form location in both groups (F(3,36) = 41.0, p < 0.01).
Central auditory processing deficits have been reported in patients after TBI34, and, similar to those in human 
TBI studies, auditory assessments have been used to identify impairments in basic and/or more complex auditory 
processing in rodent models of brain injury36–38. To assess auditory temporal processing, rats were tested for audi-
tory gap detection. For CN2097-treated rats, paired samples t-tests revealed significant differences between cued 
and uncued peak response scores at the gap durations of 20 (p < 0.001), 30 (p < 0.01), 40 (p < 0.01), 50 (p < 0.01), 
75 (p < 0.01), and 100 ms (p < 0.01) (Fig. 6C), indicating significant detection of these cue durations. In com-
parison, for vehicle-treated rats, paired samples t-tests revealed significant differences between cued and uncued 
peak response scores at 30 (p < 0.05), 40 (p < 0.05), 75 (p < 0.05), and 100 ms (p < 0.05) (Fig. 6C), indicating sig-
nificant detection at fewer gap durations in contrast to CN2097-treated rats. However, results from 2 treatments 
(TBI-vehicle, n = 6, and TBI-CN2097, n = 8) by 9 gaps (2–100 ms) repeated measures ANOVA revealed no effect 
of treatment (F(1,12) = 0.05, p = 0.83) (Fig. 6C). In addition, a significant effect of gap duration (F(1,12) = 93.9, 
p < 0.001) indicated that as gap duration increased, detection for both treatment groups improved in a similar 
manner. In contrast, when both groups were presented with a more complex tone order discrimination task 
(Fig. 6D), results from an independent samples t-test revealed a significant effect of Treatment (t(1,13) = 12.7, 
p = 0.004), with CN2097-treated rats showing superior detection when compared to vehicle-treated animals. 
In this complex task, a paired samples t-test revealed significant differences between cued and uncued peak 
responses for CN2097-treated animals (p < 0.01), indicating significant detection of the tone reversal. In con-
trast, vehicle-treated rats showed no difference between cued and uncued peak responses (p = 0.43), indicating 
an inability to detect the tone pair reversal. These findings suggest that TBI differentially affects spatial learning 
and auditory processing domains and that treatment with CN2097 can improve complex auditory processing 
after injury.
Figure 4. Presynaptic mechanisms are not involved in TBI-dependent LTP impairment and CN2097-induced 
LTP restoration. (A) Paired pulse ratios (PPRs) for vehicle- and CN2097-treated rats in both hemispheres at 
1d (top) and 3 d (bottom) after TBI at baseline (BL) and after LTP induction (LTP). (B) Examples of fEPSP 
traces representing averages of 10 responses at baseline in the contralateral (Contra-Hip, black) and ipsilateral 
(Ipsi-Hip, red) hippocampi in vehicle- (top) and CN2097-treated (bottom) rats at 3 d following TBI. Results 
indicate no differences between groups. (C) Interhemisphere ratios (Ipsi/Contra) of PPR results at baseline (left) 
and after LTP induction (right) for vehicle- (yellow) and CN2097-treated (blue) rats. Neither TBI nor CN2097 
treatment modifies PPRs. Data represent mean ± SEM.
Figure 5. Timeline for behavioral studies including relative dose timing and weeks of MWM and auditory 
testing.
www.nature.com/scientificreports/
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The effect of CN2097 on post-traumatic loss of neural tissue. Regional volume analysis of 14 brains 
(vehicle-treated rats, n = 6, and CN2097-treated rats, n = 8) was performed after the completion of behavioral 
tests. This analysis included the ipsilateral and contralateral cerebral cortices, hippocampi, and the corpus cal-
losum. For vehicle-treated rats, repeated measures ANOVA for 2 hemispheres (ipsilateral and contralateral) by 
3 brain regions (cerebral cortex, hippocampus, and corpus callosum) revealed a significant main effect of hemi-
sphere (F(1,10) = 11, p < 0.05), indicating that the volume of the ipsilateral hemisphere was significantly smaller 
compared to the contralateral hemisphere. Paired samples t-tests revealed significant differences between the 
volumes of ipsilateral and contralateral cerebral cortices (p < 0.01) and the corpus callosum (p < 0.01) in this 
group of rats (Fig. 7). Similarly, for CN2097-treated animals, repeated measures ANOVA for 2 hemispheres by 
3 brain regions (as described above) revealed a significant main effect of hemisphere (F(1,14) = 39.8, p < 0.05), 
indicating that the structures in the ipsilateral hemisphere were significantly smaller than those in the contralat-
eral hemisphere. As with vehicle-treated rats, the paired samples t-tests revealed that in CN2097-treated ani-
mals, main effects were a product of significant reductions in volumes of cerebral cortices (p < 0.001) and corpus 
callosum (p < 0.001) ipsilateral to injury (Fig. 7). No significant differences were observed between ipsilateral 
and contralateral hippocampi in two treatment groups. These findings indicate that the TBI model used in this 
study produces gross structural reductions in various brain areas ipsilateral to injury. Further analysis involving 
independent samples t-tests for the above-described brain areas across the treatment groups showed no effect 
Figure 6. Morris water maze and probe trial performance, and auditory sensory outcome after TBI. The line 
graph (A) shows a significant reduction in latency to reach the hidden platform for injured rats treated with 
CN2097 at a dose of 10 mg/kg injected i.p. at 1 and 2 h post-TBI (TBI CN2097; n = 8) and vehicle (0.9% NaCl) 
(TBI Vehicle; n = 6). The bar graph (B) shows that both groups spent significantly more time in the platform 
quadrant when compared to non-platform quadrants, suggesting comparable memory performance in both 
groups for the former platform location during the probe trial. Graphs also show (C) comparable basic auditory 
temporal processing of silent gaps in white noise for both groups and (D) a significant improvement of complex 
tone order discrimination in rats treated with CN2097 versus those receiving vehicle (*p = 0.004). +Indicates 
significant (p < 0.05) difference between cued and uncued responses for CN2097-treated rats. #Indicates 
significant (p < 0.05) difference between cued and uncued responses for vehicle-treated rats. Data represent 
mean ± SEM.
www.nature.com/scientificreports/
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of treatment on the volumes of these areas (Fig. 7). These results indicate that with the CN2097 dose used the 
improvements seen in other measures in CN2097-treated animals do not extend to the gross structural level.
Discussion
Several pathophysiological processes triggered by neurotrauma, including glutamate excitotoxicity, oxidative 
stress, and neuroinflammation, are initiated within the first hours after TBI, but result in prolonged neurode-
generation39. At synapses, the activation of NMDARs has been shown to promote the release of BDNF40 required 
for survival3 and cognition6, 12. Although numerous studies have shown the neuroprotective potential of BDNF, 
treatment with BDNF is limited by its short plasma half-life and poor BBB penetration41. Here, using the CCI rat 
model of TBI, we demonstrate the therapeutic efficacy of CN2097, a novel cyclic peptide that enhances synaptic 
BDNF signaling12 and blocks NMDAR-mediated cell-death signaling13.
Therapeutic interventions aimed at reducing post-traumatic neuroinflammation and limiting the influx of 
inflammatory cells diminish the loss of neural tissue and improve functional outcome after brain injury39, 42, 43. 
Here we report that post-injury treatment with CN2097 significantly attenuates JNK signaling, lowers the syn-
thesis of proinflammatory cytokines, TNF-α and IL-1β, and diminishes the influx of inflammatory cells into 
the injured brain parenchyma. Although the cellular mechanisms underlying the anti-inflammatory activity of 
CN2097 are poorly understood, it appears that CN2097 interferes with the initiation/progression of inflammatory 
cascade. Similarly, the TrkB agonist, 7,8-dihydroxyflavone, has been reported to decrease microglial release of 
IL-1β and TNF-α by downregulating MAPK signaling24. CN2097 may also improve functional outcome due to 
its inhibitory effect on the post-traumatic synthesis of MMP9. This conclusion is supported by previous observa-
tions that the genetic or pharmacological interference with MMP9 synthesis reduces neuronal loss and improves 
neurobehavioral performance after injury44.
Neuroinflammation encompasses a broad range of pathophysiological phenomena, which include the pro-
duction of soluble proinflammatory mediators, the invasion of inflammatory cells, and the activation of micro-
glia. A significant increase in brain production of proinflammatory cytokines and chemokines occurs within 
hours after TBI, but usually lasts for a relatively short period of time, less than 24 h, after injury45. Similarly, the 
post-traumatic invasion of neutrophils is observed in the early stage post-TBI; in comparison, monocytes infil-
trate the traumatized parenchyma within days after TBI. These phenomena coincide temporally with a peak in 
neuronal death resulting from TBI46, suggesting that anti-inflammatory intervention initiated shortly after TBI is 
critical for attenuating the post-traumatic loss of neural tissue. Therefore, an early, single dose of a drug mitigating 
Figure 7. Brain regional volume analysis in CN2097- versus vehicle-treated rats. Photomicrographs (A) show 
coronal brain sections from ipsilateral and contralateral hemispheres from vehicle- and CN2097-treated rats, 
demonstrating comparable injury profiles. Bar graph (B) shows regional brain volume measurements for 
vehicle-treated (TBI Vehicle; n = 6) and CN2097-treated (TBI CN2097; n = 8) rats, indicating comparable 
ipsilateral and contralateral regional brain volumes of the cerebral cortex, hippocampus, and corpus callosum. 
*Indicates significant (p < 0.01) differences between ipsilateral and contralateral hemispheres for both 
treatment groups. Data represent mean ± SEM.
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post-traumatic neuroinflammation could be therapeutically efficacious. This idea is not only supported by the 
present results, but also by the data from other laboratories47, 48. While post-traumatic neuroinflammation is also 
characterized by a long-lasting activation of microglia49, it is presently unclear what role these glial cells might 
play in the chronic phase after injury and how to approach this therapeutically. It has been shown, for example, 
that microglia may have a neuroprotective role after brain injury50, which suggests that more research is needed 
to better understand this aspect of post-traumatic neuroinflammation.
In agreement with previous studies5, 30, 31, LTP was impaired in the ipsilateral relative to the contralateral 
hippocampus 1 and 3 days after injury, and CN2097 was found to attenuate these LTP deficits. We observed 
no difference in paired-pulse facilitation (PPF), a general index of excitation-neurotransmitter release cou-
pling. BDNF plays a key role in synaptic transmission, and proinflammatory cytokines, such as IL-1β, suppress 
TrkB-induced signaling required for LTP stabilization16. The ability of CN2097 to enhance TrkB-mediated PLCγ 
and the PI3K-Akt activity12, required for the induction28 and late-phase LTP51, may play a role in post-TBI recov-
ery of hippocampal LTP52. Cytokines are reported to impair LTP via the JNK pathway activation22, 29, and we 
observed a reduction in JNK signaling in the hippocampus of CN2097-treated animals. An improvement in LTP 
performance and functional outcome in CN2097- versus vehicle-treated rats is also consistent with the ability of 
this compound to attenuate post-traumatic neuroinflammation.
Sensory cortices are highly susceptible to experience-dependent plasticity relying on LTP-dependent mecha-
nisms as well as trauma-induced reorganization53, 54. This study shows that while the basic auditory discrimina-
tion appears to be intact in rats sustaining TBI, complex tone pair discrimination is impaired after injury. Thus, 
when rats were presented with a cortically mediated oddball tone order discrimination task at 4 weeks after injury, 
CN2097-treated rats performed significantly better than those receiving vehicle. Although we did not include a 
sham-injured group in this comparison, results show that only the CN2097-treated rats were able to significantly 
detect the complex tone reversal, reinforcing the significant treatment effect. These findings parallel reports of 
impaired event-related potential activity and central auditory acuity in TBI patients34, 55–57.
As CN2097 was found to attenuate hippocampal LTP deficits at 1 and 3 days after injury, we examined if 
CN2097 treatment could have an impact on spatial learning and memory. To this end, we employed the MWM 
paradigm, which has been used to assess cognitive deficits in TBI models54, 58. Results showed that both the 
vehicle- and CN2097-treated TBI groups performed similarly across all days of testing. The learning and memory 
profiles of both groups in the present study are comparable to those reported for control animals from other stud-
ies, suggesting that the severity of TBI might not have been sufficient to reach a threshold for behavioral impair-
ment on the MWM task35, 58, 59. Moser and colleagues showed that direct lesions of dorsal hippocampus have to 
exceed 20% of the hippocampal tissue to consistently affect spatial learning, whereas the comparable lesions of the 
ventral hippocampus have no effect on performance in the MWM60. The disassociation between spatial learning 
and auditory discrimination observed in the current study suggests that tone-order discrimination may be a more 
sensitive measure of treatment efficacy in experimental TBI compared to MWM. The significance of our findings 
cannot be overstated as our relatively novel behavioral tests provide a highly sensitive means of assessing higher 
order sensory processes in the rodent model, which are adversely affected in TBI patients. Increasingly, these 
sensory processing tools have been employed in human clinical settings as outcome assessment methods given 
the critical role of auditory sensory discrimination in mediating normal speech function34, 61. These methods 
have also been used to evaluate models of developmental brain injury, which parallel sensory processing deficits 
seen in human language learning impaired populations62. The acoustic discrimination methods employed in the 
current study are highly sensitive to subtle cortical disruption34, and are translatable into clinical practice.
In this study, we showed that post-traumatic treatment with CN2097 (injected i.p. at a dose of 10 mg/kg at 
1 and 2 h after injury) improves synaptic plasticity and behavioral outcome; however, CN2097 administered at 
this dose did not appear to reduce the volume of post-traumatic lesion. The 10-mg/kg dose of CN2097 used was 
based on the intravitreal dosing of this peptide to attenuate NMDA-induced poly-ADP-ribosylation in the ret-
ina in an in vivo model of retinal toxicity13, and the dosing of intrathecally injected CN2097 to define its central 
anti-nociceptive effects63. In future studies, it will be necessary to assess the optimal dose of this cyclic peptide that 
could also reduce the neuronal loss resulting from injury. The rationale for beginning treatment at 1 h post-TBI 
was based on the reasonable assumption that within this time frame after injury the patient could be treated at 
the scene or shortly after arriving at the hospital. Since the patient may not always be available for therapeutic 
intervention at such early time after TBI, it will also be important to define the potential therapeutic time-window 
for delayed treatment with CN2097.
Traumatic brain injury remains a major health and socioeconomic problem. As the severity of secondary 
injury largely determines functional outcome after TBI, early intervention aimed at mitigating secondary injury 
is critical for improving long-term neurological outcome. The complex and interdependent nature of pathophys-
iological events resulting from TBI may explain why single-mechanism neuroprotective interventions have failed 
to demonstrate consistent improvement of outcome in neurotrauma patients2. Our results suggest that the devel-
opment of multifunctional drugs, such as CN2097, that simultaneously reduce neuroinflammation and facilitate 
synaptic plasticity, will have significant therapeutic potential to promote functional recovery after TBI.
Materials and Methods
Controlled cortical impact injury. Adult male Long-Evans weighing 200–250 g (Harlan, Indianapolis, IN) 
were kept at 22 °C with a 12-h light cycle and maintained on standard pellet rat chow and water ad libitum. The 
surgical and animal care procedures used in this study were approved by the Animal Care and Use Committee 
of Rhode Island Hospital and conformed to international guidelines on the ethical use of animals. All experi-
ments were performed in accordance with these guidelines and regulations. Four to six rats per group/time point 
were used for most experiments with the exception of behavioral studies in which 6–8 animals was tested. The 
controlled cortical impact (CCI) model of TBI was employed as previously described14, 26, 64. In brief, rats were 
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anesthetized with i.p. pentobarbital sodium (60 mg/kg) and a 4-mm craniotomy was performed on the right side 
of the skull to expose the dura, with the center of the opening located 3 mm posterior to the bregma and 2.5 mm 
lateral to the midline. The velocity of impact was 5 m/sec and the duration of impact was 50 msec. The diameter 
of the impactor tip was 2.5 mm and the depth of brain deformation was set at 2.5–3.0 mm. For all types of exper-
iments, animals were injected i.p. with CN2097 (10 mg/kg) or vehicle (0.9% NaCl) at 1 and 2 h post-TBI. For 
Western blot analysis, animals (n = 4 rats/group) were sacrificed at 4 h or 24 h after TBI and the cerebral cortical 
or hippocampal samples were collected. The effect of CN2097 on hippocampal LTP was evaluated at 1 and 3 days 
post-TBI. The effect of CN2097 on neurobehavioral outcome after TBI was tested as shown in Fig. 5.
Western blotting. Proteins from brain tissue samples were extracted using RIPA buffer (150 mM NaCl, 
50 mM Tris-HCl, pH 7.4, 2 mM EDTA, 1% Triton X-100, 0.5% deoxycholate, 0.1% SDS), containing protease 
inhibitors (1 mM benzamidine, 100 U/ml aprotinin, 20 μg/ml antipain, 20 μg/ml leupeptin, 1 μg/ml pepstatin A, 
1 mM PMSF) and phosphatase inhibitors (10 mM sodium pyrophosphate, 1 mM sodium orthovanadate, 1 mM 
sodium fluoride, 1 mM β-glycerophosphate). Proteins were resolved via SDS-polyacrylamide gel (4–12%) elec-
trophoresis under reducing conditions and were transferred onto 0.2-μm nitrocellulose membranes (Invitrogen, 
Carlsbad, CA). After blocking with 5% ECL Advance blocking agent (GE Healthcare, Little Chalfont, UK) for 1 h 
at room temperature, the membranes were incubated with primary antibodies overnight at 4 °C. The following 
antibodies were used: rabbit polyclonal anti-human TNF-α (diluted 1:500) and anti-human IL-1β (4 µg/mL) from 
Novus Biologicals (Littleton, CO); rabbit monoclonal anti-human matrix metalloproteinase 9 (MMP9) (0.4 µg/
mL) from Abcam (Cambridge, MA); mouse monoclonal anti-rat CD68 (clone ED1; 0.5 µg/mL) from Serotec 
(Oxford, UK) and anti-chicken α-tubulin (clone DM1A; diluted 1:5000), JNK and p-JNK (Thr183/Tyr185) from 
Cell Signaling (Danvers, MA). Membranes were subsequently incubated with horseradish peroxidase-conjugated 
anti-rabbit or anti-mouse antibody (Cell Signaling; diluted 1:5000) for 1 h at room temperature. Detection was 
performed using Lumigen TMA-6 (Lucien, Southfield, MI) or ECL Prime (GE Healthcare) chemiluminescence 
detection reagents. The Bio Imaging System Chemo Genius2 (Syngene, Frederick, MD) was used for Fig. 1 and 
the Bio-Rad ChemiDoc XRS+ system (chemi hi res and exposure time of 17–20 seconds) for Fig. 2. In the analysis 
of the optical density of the bands on immunoblots, the levels of proteins of interest were normalized to the levels 
of α-tubulin. The analysis of optical density was performed using ImageJ software (http://rsb.info.nih.gov/ij/).
In vitro slice preparation. Rat brains were immersed in cold (5–7 °C), oxygenated (95% O2/5% CO2) arti-
ficial cerebrospinal fluid (ACSF) containing (in mM): 126 NaCl, 3 KCl, 1.25 NaH2PO4, 1 MgSO4, 2 CaCl2, 26 
NaHCO3, 10 glucose. Coronal slices (500 µm), including the dorsal hippocampus and adjoining cerebral cortex, 
were cut using a vibratome. Slices were transferred to a temperature controlled (34 ± 0.5 °C) interface chamber 
and superfused with oxygenated ACSF at a rate of 1–2 mL/min. Slices were allowed to recover for at least one hour 
prior to the start of recordings.
Stimulation and field potential recordings. Animal procedures were performed in compliance with 
the US Department of Health and Human Services and the IACUC animal care guidelines at Brown University. 
Recording electrodes pulled from borosilicate glass pipettes (resistance < 1MΩ) were placed within the CA1 stra-
tum radiatum for extracellular recordings. Synaptic responses were elicited by stimulation of the Schaffer collat-
erals with square wave pulses using concentric bipolar stimulation electrodes. To assess paired-pulse ratio, which 
is a measure for presynaptic release probability, each stimulation consisted of two pulses separated by 50 ms. 
Extracellular postsynaptic field potentials were recorded using an AxoClamp2B amplifier (Axon instruments) and 
EX1 differential amplifier (Dagan), and digitized at 10 kHz. Data was acquired using Igor Pro (Wave Metrics) and 
Neuromatic (www.neuromatic.thinkrandom.com). For LTP induction, the stimulus intensity eliciting 50% of the 
maximum amplitude was used for all measurements before and after LTP induction. Baseline amplitudes were 
recorded for 20–30 minutes using single stimuli applied every 30 sec. Following a stable baseline period, LTP was 
induced by two sets of high-frequency stimulation (HFS) at 100 Hz for 1 sec, 20 sec apart. Extracellular postsyn-
aptic field potential slopes were measured and LTP values were expressed as percentage of mean baseline ± SEM. 
Paired two-tailed t-tests were used for statistical analysis. For PPR analysis, ratios of the 2nd to the 1st pulse were 
assessed and compared between treatment groups. Because the uninjured contralateral hemispheres exhibited the 
same magnitude of LTP in vehicle- and CN2097-treated rats, we used the contralateral hemisphere as a control for 
treatment-dependent effects. We then calculated the ratios between the contralateral and ipsilateral hemispheres 
to assess the ability of CN2097 to improve LTP in the ipsilateral hippocampus in which it was impaired by injury.
Morris water maze. Briefly, the MWM testing was conducted one week following CCI in a round tub 
122 cm in diameter filled with water at 22 °C with a 20-cm diameter transparent plexiglass submerged platform, 
consistently placed in the southeast (SE) quadrant, 2 cm below the water surface (see Fig. 5 for timeline). Fixed, 
extra-maze cues included posters with geometric shapes on adjacent walls. On each of five testing days, rats 
underwent four trials, with each trial starting from a different randomly selected compass point (N, S, E, W). On 
day one, trial one, each rat was placed on the platform for 10 s, removed from the platform and then released from 
one of the starting locations. Each trial was limited to a maximum duration of 45 s. Animals unable to reach the 
platform within this time were guided to the target and remained there for 5 s. The latency to reach the platform 
for each trial across days was recorded using Ethovision XT (Noldus) behavioral tracking software. Total time to 
reach the platform for each rat was summed across the four trials each day and used as the dependent variables. 
On day six, all rats were given a single 45 s probe trial, where the platform was removed and the time spent in the 
four quadrants was recorded (NW, NE, SW, SE/Platform quadrants). Greater time spent in the former platform 
zone is indicative of memory for the platform location.
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Auditory discrimination. Auditory testing took place during the fourth week post-TBI (see Fig. 5 for time-
line) and involved a modified acoustic startle paradigm that has been discussed extensively elsewhere36, 65, 66. 
Two tasks were presented (gap detection and odd-ball tone pair discrimination), which have been widely used to 
assess auditory temporal processing in humans and rodent models67, 68. Briefly, the startle modification paradigm 
involved the presentation of an auditory cue prior to a startle-eliciting stimulus (SES). The SES elicits an acoustic 
startle reflex (ASR) and if the preceding auditory cue is detected, the intensity of the ASR is reduced. Stimulus files 
were played through a Pyle PT8000CH amplifier connected to four 200-Watt PCB4 Pyle speakers (Pyle Audio 
inc., Brooklyn, NY), with sound levels calibrated by sound-level meter66. Attenuated response scores (ATT) were 
calculated from the peak ASR using the formula ([mean cued response/mean uncured response] × 100) and used 
as dependent measures. Thus, lower attenuation scores reflect greater relative detection of the cued stimuli. First, 
rats were given one day of testing on a gap detection task (0, 2, 5, 10, 20, 30, 40, 50, 75, or 100 ms). The gap session 
included 300 trials, each consisting of the presentation of variable duration silent gaps embedded in continuous 
75-dB broadband white noise. Each silent gap was presented 50 ms prior to a 105-dB burst of white noise. During 
uncued trials, the 105-dB burst immediately followed the 75-dB white noise65, 69. Second, the oddball session 
was comprised of 104 trials. This procedure involved the repeated presentation of a background 75-dB, high-low 
frequency tone sequence (2300–1100 Hz) separated by a within-stimulus inter-stimulus interval (ISI) of 225 ms. 
Each sequence was separated by a between sequence ISI of 425 ms (200 ms greater than the inter-stimulus interval 
to maintain perceptual contiguity of the tone-pair). On uncured trials, the last tone sequence was followed by 50 
ms of silence, then by the 105-dB/50 ms SES. On cued trials, a reversal of the tone sequence occurred (low-high; 
1100–2300 Hz) followed by 50 ms of silence, and then the SES.
The assessment of changes in brain regional volumes. After behavioral testing, rats were transcar-
dially perfused with 200 mL of 0.9% NaCl solution and 200 mL of 10% phosphate-buffered formalin. Each brain 
was sectioned using a vibrating microtome at 100 µm in the coronal plane. Every section from approximately 
–1.0 to –4.2 mm from bregma was mounted on glass slides, stained using a standard cresyl violet protocol, and 
cover slipped in preparation for volume analysis. Regions of interests (cerebral cortex, hippocampus, and corpus 
callosum) were traced in Stereoinvestigator (MBF Bioscience, Williston, VT) and volume estimates were calcu-
lated in the same software program using Cavalieri’s unbiased estimator of volume derived from the serial section 
reconstruction70.
Peptide synthesis. CN2097 was synthesized using N-(9-fluorenyl)methoxycarbonyl (Fmoc)-solid phase 
peptide synthesis protocols20, as previously described13. CN2097 was purified by RP-HPLC, lyophilized, and 
exchanged with HCl. Peptide purity was in the range of 90–95% as determined using high-resolution time of 
flight AXIMA-performance MALDI TOF-TOF mass spectrometer (Shimadzu).
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